Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 10, 2000, Pages 2784-2793

  Suling, W J ^a   Seitz, L E ^a   Pathak, V ^a   Westbrook, L ^a   Barrow, E W ^a   Zywno Van Ginkel, S ^a   Reynolds, R C ^a   Piper, J R ^a   Barrow, W W ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 DEAZAPTERIDINE DERIVATIVE; ANTIMYCOBACTERIAL AGENT; DIHYDROFOLATE REDUCTASE; FUNCTIONAL GROUP; PIRITREXIM; PTERIDINE DERIVATIVE; RECOMBINANT ENZYME; SRI 20094; SRI 8686; TRIMETREXATE; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION;

ANTI-INFECTIVE AGENTS; CELL LINE; CELL SURVIVAL; COLONY COUNT, MICROBIAL; FOLIC ACID ANTAGONISTS; HUMAN; MACROPHAGES; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; MONOCYTES; MYCOBACTERIUM; PTERIDINES; PYRIMIDINES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, U.S. GOV'T, P.H.S.; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 0033802522     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.10.2784-2793.2000     Document Type: Article

References (34)

1. Basis of selectivity of antibacterial diaminopyrimidines
2. Use of microsphere technology for sustained and targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages
3. Structure-activity relationships of dihydrofolate inhibitors
4. The clinical pharmacology of methotrexate. New applications of an old drug
5. Structure-activity relationships of dihydrofolate reductase inhibitors
6. Microplate Alamar Blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium
7. New benzylpyrimidines: Inhibition of DHFR from various species. QSAR, CoMFA and PC analysis
8. Purification and characterization of dihydrofolate reductase from methotrexate-resistant human lymphoblastoid cells
9. Symposium on trimethoprim-sulfamethoxazole
10. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: Synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino) methyl]-pyrido [2,3-d] pyrimidines
11. Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and potential antipneumocystis, antitoxoplasma, antitumor agents
12. 2,4-Diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases
13. Molecular aspects and mechanism of action of dihydrofolate reductase inhibitors
14. Effect of substrate decomposition on the spectrophotometric assay of dihydrofolate reductase
15. Synthesis of new 2,4-diamino-5-benzylpyrimidines active against various bacterial species
16. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs
17. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone
18. Conformational analysis of lipophilic antifolates: Crystal structure of 2-amino-4-oxo-6-adamantylpteridine and a comparison of its binding to bacterial and avian dihydrofolate reductase
19. In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex
20. Receptor-based design of novel dihydrofolate reductase inhibitors: Benzimidazole and indole derivatives
21. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations
22. Expression and site-directed mutagenesis of human dihydrofolate reductase
23. Advances in chemotherapy of malaria
24. Dihydrofolate reductase as a therapeutic target
25. In vitro and in vivo results of brodimoprim and analogues alone and in combination against E. coli and mycobacteria
26. In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex
27. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase
28. History and future of antimicrobial diaminopyrimidines
29. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin and ciprofloxacin, against Mycobacterium tuberculosis and Mycobacterium avium complex
30. Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies
31. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis
32. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes
33. Identification and cloning of the Mycobacterium avium fol A gene, required for dihydrofolate reductase activity